$3.8m R&D Rebate Received & Overseas Finding Approved
Filed with ASX · · 2 pages · English
Summary by 6ix AI
EMvision Medical Devices Ltd. has announced the receipt of a significant R&D tax refund related to eligible activities from a previous financial year, which strengthens its funding position. Additionally, the company has received approval for its Advance Overseas Finding application, which covers overseas expenditures for its pivotal trial and market access activities. This approval allows EMvision to access a cash rebate on eligible overseas R&D expenditures for several upcoming financial years.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EMvision Medical Devices Ltd. on 6ix
Earlier from EMvision Medical Devices
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- S&P DJI Announces March 2026 Quarterly Rebalance
- EMVision Medical Devices to Present at Australia Investor Day February 26th
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from EMvision Medical Devices
- emu Pivotal Trial Expansion Adds Acute Ischaemia Detection
- EMVision to Receive $1.17M IGP Grant Instalment
- Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
- Appendix 4E & Annual Report to 30 June 2026
- emu Pivotal Trial Recruitment Surpasses 200 Patients
Follow EMvision Medical Devices into a list and get an email when it puts out news.
Follow EMvision Medical Devices